辉瑞停止减肥药Danuglipron的开发,诺和诺德等竞争对手或受益

老虎资讯综合
14 Apr

辉瑞宣布停止减肥药Danuglipron的开发。辉瑞表示,参与者出现了潜在的药物引起的肝损伤。

赛道竞争对手诺和诺德盘前拉升,截至发稿涨近4%。同时,Viking Therapeutics盘前大涨逾19%,礼来涨1.47%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10